Related Experiment Videos
Prognostic and predictive indicators in operable breast cancer.
Alessandro Morabito1, Elena Magnani, Massimo Gion
1Division of Medical Oncology, Azienda Ospedaliera San Filippo Neri, Rome, Italy.
Clinical Breast Cancer
|March 15, 2003
Summary
Breast cancer management is complex due to its heterogeneity. Advances in molecular understanding are identifying new biomarkers to predict treatment response and patient prognosis.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Medicine
Background:
- Breast cancer presents biological heterogeneity, complicating clinical management and treatment selection.
- Recent advancements have improved understanding of the molecular mechanisms driving cancer development.
- This enhanced knowledge facilitates the identification of novel biomarkers for prognosis and treatment prediction.
Purpose of the Study:
- To review established and emerging biomarkers in breast cancer.
- To discuss their role in predicting prognosis and guiding adjuvant treatment decisions.
- To highlight the need for prospective studies to validate new biomarkers.
Main Methods:
- Review of current literature on breast cancer biomarkers.
- Analysis of established prognostic and predictive factors.
- Discussion of promising novel biomarkers and their potential clinical utility.
Main Results:
- Established factors include axillary nodal status, age, tumor size, grade, and hormone receptor status.
- Emerging biomarkers like p53, HER2/neu, angiogenesis, and proliferation index show promise.
- Further prospective clinical validation is required for these new markers.
Conclusions:
- Biomarker identification is crucial for personalized breast cancer treatment.
- Established biomarkers guide current adjuvant therapy selection.
- Prospective studies are essential to confirm the clinical value of novel biomarkers for improved patient outcomes.